吉林敖东(000623) - 2023 Q4 - 年度财报

Financial Performance - The company reported a non-operating income of ¥35,522,895.57 from the disposal of non-current assets in 2023, a significant increase from ¥1,486,450.08 in 2022[29]. - Government subsidies recognized in the current period amounted to ¥94,193,045.36, up from ¥82,482,380.98 in the previous year, indicating a growth of approximately 9.8%[29]. - The company achieved a profit of ¥118,563,625.81 from investments where the cost was less than the fair value of identifiable net assets acquired, compared to ¥610,907,708.05 in 2022[29]. - The total impact of non-recurring gains and losses after tax and minority interests was reported as ¥146,524,768.26, reflecting a decrease from the previous year's figures[29]. - The company's operating revenue for 2023 reached ¥3,449,123,301.81, representing a 20.25% increase compared to ¥2,868,211,464.89 in 2022[45]. - The net profit attributable to shareholders decreased to ¥1,459,879,678.96, down 18.02% from ¥1,780,642,529.11 in the previous year[45]. - The net cash flow from operating activities was ¥1,313,354,910.70, a decline of 15.63% compared to ¥1,530,399,881.11 in 2022[45]. - Basic earnings per share fell to ¥1.2971, down 17.35% from ¥1.5692 in 2022[45]. - Total assets increased by 3.48% to ¥32,266,140,600.63 from ¥31,172,579,530.80 at the end of 2022[45]. - The net assets attributable to shareholders rose by 4.52% to ¥27,211,602,992.20 from ¥26,036,584,656.86 at the end of 2022[45]. Market Trends and Opportunities - The global pharmaceutical market is projected to exceed $2 trillion by 2028, with a compound annual growth rate of 4.8% from 2022 to 2028[55]. - The global chemical drug market accounted for 74.2% of the pharmaceutical market in 2023, while the biological drug market held 25.8%[55]. - The average price reduction for newly negotiated drugs in the national medical insurance directory was 60.1%[58]. - The company is expected to benefit from the "Belt and Road" initiative, which will enhance the international market for traditional Chinese medicine[57]. Product Development and Innovation - The company has established a multi-wheel-driven development model encompassing "pharmaceuticals + finance + health" and is expanding into health food and agriculture sectors[66]. - The company is committed to enhancing the quality of its products and accelerating technological innovation in the pharmaceutical industry[64]. - The company's pharmaceutical and retail business achieved revenue of 2,983.48 million yuan, accounting for 86.50% of total revenue, with a year-on-year growth of 20.97%[97]. - The traditional Chinese medicine (TCM) segment saw a revenue increase of 27.19% year-on-year, focusing on three core product clusters[97]. - The company has 616 production approval numbers, including 311 for TCM and 305 for chemical drugs, with 47 unique products and formulations[99]. - The company is focusing on expanding its product line with new formulations such as Qihuang Yishen Oral Liquid and Tian'e Buxin Oral Liquid, targeting kidney health and energy restoration[100]. - The company emphasizes the importance of regulatory approvals, as seen with the National Drug Approval Numbers for its products, ensuring market readiness[100]. - Future product development will likely focus on enhancing existing formulations and introducing innovative health solutions to meet consumer demand[100]. - The company is committed to research and development, aiming to improve product efficacy and expand its therapeutic applications[100]. Sales and Market Expansion - The company has launched several proprietary products aimed at various health conditions, including Danxiang Qingzi Granules for hyperlipidemia and Du Zhi Wan for ischemic stroke recovery[100]. - The company is actively pursuing market expansion strategies, particularly in the herbal medicine sector, to enhance its competitive edge[100]. - The company has established a standardized procurement process to enhance quality and efficiency, aiming to reduce costs while ensuring timely supply of materials[107]. - The company expanded its retail presence by adding 19 new 24-hour pharmacies and establishing online stores on major e-commerce platforms[172]. - The company plans to enhance its market coverage and share through strategic product development and marketing initiatives in pediatric and gynecological fields[185]. Corporate Governance and Compliance - The company emphasized the importance of risk awareness regarding forward-looking statements made in the report, urging investors to understand the differences between plans, forecasts, and commitments[15]. - The company’s financial report for the year shows a commitment to transparency, with all board members present for the report's review[4]. - The company has maintained its continuous supervision responsibilities through its appointed sponsor institution during the reporting period[11]. - The company continues to focus on quality management, adhering to higher internal control standards than national regulations[145]. - The company is committed to ensuring the efficacy and safety of its products through rigorous testing and compliance with regulatory standards[134]. Recognition and Achievements - The company has been recognized as a "Chinese Time-honored Brand" by the Ministry of Commerce, reflecting its historical significance and market presence[66]. - The brand "Aodong" has been recognized as one of the "Top 500 Most Valuable Brands in China" for 18 consecutive years, with a brand value of ¥131.94 billion[114]. - The company has received numerous honors, including being recognized as a national high-tech enterprise and a model for harmonious labor relations[96].